Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data.

Saffie Vega, Isabel; Sapunar Zenteno, Jorge; Buscaglia Fernandez, Felipe; Reyes Cosmelli, Felipe; Lagos Chavez, Rodrigo; Chahuán Manzur, Badir

Saffie Vega, Isabel; Sapunar Zenteno, Jorge; Buscaglia Fernandez, Felipe; Reyes Cosmelli, Felipe; Lagos Chavez, Rodrigo; Chahuán Manzur, Badir.

Afiliación

Saffie Vega I; Breast Oncologic and Reconstructive Surgery Unit, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7500691, Chile.
Sapunar Zenteno J; Epidemiologic and Clinical Research Unit, Department of Cancer Research, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7500691, Chile.
Buscaglia Fernandez F; Epidemiologic and Clinical Research Unit, Department of Cancer Research, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7500691, Chile.
Reyes Cosmelli F; Department of Internal Medicine, School of Medicine, Universidad de La Frontera, Temuco 4811230, Chile.
Lagos Chavez R; Pathology Anatomy Unit, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7500691, Chile.
Chahuán Manzur B; Medical Oncology Unit, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7500691, Chile.

Ecancermedicalscience ; 16: 1338, 2022.

Article en En | MEDLINE | ID: mdl-35242219

Palabras clave

HER2 positive; breast cancer; neoadjuvant chemotherapy; pathologic complete response; pertuzumab; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ecancermedicalscience Año: 2022 Tipo del documento: Article País de afiliación: Chile

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google